May 2016
Control persons are vital to studies looking at diseases. LIH spoke to Dany, the 100th control person of the Parkinson’s disease study of the NCER-PD.
NCER-PD stands for National Centre of Excellence in Research on Parkinson’s Disease. It represents a joint effort between four partners in Luxembourg that unite their expertise in Parkinson’s disease: Luxembourg Centre for Systems Biomedecine (LCSB), Centre Hospitalier de Luxembourg (CHL), Integrated Biobank of Luxembourg (IBBL) and Luxembourg Institute of Health (LIH).
This collaboration between all the research institutions focusing on Parkinson’s disease in Luxembourg has been funded by the FNR since spring 2015 when the Centre was launched.
In order to answer the urgent questions surrounding the occurrence of Parkinson’s disease, researchers need to analyse clinical data and samples from hundreds of patients and healthy control persons.
The active participation in the Luxembourgish Parkinson’s study is therefore an important prerequisite for the success of the NCER-PD research project.
What’s your name/age?
“I’m Dany, I’m 58 years old.”
Where do you come from?
“I was born here in Luxembourg. I’m an authentic Luxembourger!”
How did you hear about the NCER-PD study, and what motivated you in participating?
“I read about it on Facebook. I’m following the science.lu page, and I always read the articles because I find them really interesting. That’s where I got to know about the study.
“What motivated me? I‘ve somehow always been interested in medicine, and seeing that such a study is taking place in Luxembourg caught my attention. It has never been done before, and it is really something important. I could get sick from Parkinson tomorrow, and I know some people who have been living with the disease for years – I can see it’s very difficult, not to have control on yourself anymore. I guess you must feel a bit trapped in your own body.
“I already volunteered for Omega 90 and Médecins du Monde, I just find it natural to help. So if I can contribute in any way to help researchers in understanding what happens and finding new treatments for Parkinson, I’m more than happy to do so!”
How was your day here?
“Very good! People are very nice, and I could ask a couple of questions to the doctor who came for the examination, so I even got to learn a few things!”
What would you tell the people who are still hesitating in participating?
“It doesn’t hurt! (laughs) Don’t be afraid! We can’t stand waiting and not doing anything – you’ve got to do something too!”
What would you tell the researchers and staff working on the project?
“Go on and … find something! The job you do is really important, even if you don’t always get the recognition you owe. So don’t stop and don’t drop the ball. What you’re doing is great and we’re counting on you!”
And to the Parkinson’s disease patients?
“Keep hoping, and don’t forget to enjoy the little things in life!”
More information
Read our feature about NCER-PD
Visit www.parkinson.lu to find how to get involved
This interview was originally featured on the website of the Luxembourg Institute of Health (LIH).
RELATED HIGHLIGHTS
October 26, 2020
Over the past two decades, Luxembourg has developed into an internationally recognised hub for science. An important driving force behind this development is Parkinson’s research. The Grand Duchy is now one of the leading locations for this field of research. This can be attributed in part to the FNR-sponsored project NCER-PD, the National Centre for Excellence in Research on Parkinson’s Disease. NCER-PD is so successful that, in 2019, the FNR gave the green light and six million euros for the second funding period.
September 16, 2020
Together with an international team of scientists, Luxembourg researchers led by FNR PEARL Chair Prof. Rejko Krüger, have clarified the cause for certain genetic forms of Parkinson’s disease. The seven-year interdisciplinary research effort also identified potential pharmacological treatments.
January 30, 2020
In 2015, the ambitious National Centre of Excellence in Research on Parkinson’s Disease (NCER-PD) was launched with the support of the FNR. This research programme brings together research institutions focusing on Parkinson’s disease in Luxembourg, with the aim of answering urgent questions on Parkinson’s disease. As of the end of 2019, the Luxembourg Parkinson’s Study has reached its ambitious goal: 800 patients and 800 controls have been recruited in Luxembourg and the Greater Region.
September 26, 2017
By the time Parkinson’s disease manifests in symptoms such as tremors, parts of the brain have already been damaged beyond repair. In a quest to shed light on the early stages of the disease, a team of researchers led by FNR ATTRACT Fellow Prof Paul Wilmes, has discovered that the gut of Parkinson’s patients differs from that of healthy people – even at early stages of the disease.
December 6, 2016
The 2016 edition of the Researchers’ Days, organised by the FNR, attracted a large audience that took part in fascinating scientific experiments and had the opportunity to mingle with the present researchers. The Luxembourg Parkinson Study (NCER-PD) was of course there too, with a booth called ‘What Parkinson’s disease feels like’. We took a closer look!
December 1, 2016
In 2015, Cyrille Thinnes was featured in our campaign ‘Spotlight on Young Researchers’, which highlighted early-career researchers with a connection to Luxembourg. At the time, Cyrille was at the University of Oxford doing a DPhil (PhD) in chemical biology. One year on, we caught up with Cyrille!
January 17, 2016
A new funding programme of the FNR facilitates the creation of a national clinical research centre with a direct impact for patients with Parkinson’s disease.